Elicio Therapeutics, Inc. Share Price

Elicio Therapeutics, Inc. Share Price

NASDAQ: ELTX | Micro Cap
$1.70
-$0.07 (-4.23%) Last updated on 30 Oct, 2026 | 19:30 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Elicio Therapeutics, Inc. Stock Performance

Open
$1.76
Prev. Close
$1.77
Circuit Range
N/A
Day Range
$1.73 - $1.76
Year Range
$1.44 - $16.00
Volume
711
Average Traded
$1.75

Elicio Therapeutics, Inc. Share Price Today

As of 30 October 2026, Elicio Therapeutics, Inc.'s share price is $1.70. The stock opened at $1.76, compared to its previous close of $1.77. During today's trading session, Elicio Therapeutics, Inc.'s share price traded between $1.73 and $1.76, with an average price of $1.75. Over the past 52 weeks, the stock has recorded a high of $16.00 and a low of $1.44. In terms of performance, Elicio Therapeutics, Inc.'s share price has declined by 83.96% over the last six months and is down 81.76% on a year-on-year basis.

Elicio Therapeutics, Inc. Share Price Chart

Line chart of the Elicio Therapeutics, Inc. price trend over the selected period. The price fell overall, ranging from 1.68 to 1.77, ending at 1.70.
$1.73$1.76
L
Show Current Price
H

Elicio Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$26.03M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.40
Revenue (TTM)
$0.00
Return On Equity (TTM)
-476.77%
Profit Margin
N/A
Debt to Equity
1.20
Quarterly Earnings Growth YoY
18.45%

Elicio Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$10.08-$7.72-$11.82-$8.22
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A23.41%-53.11%30.46%

Elicio Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars202320242025
Revenue$0.00$0.00$0.00
Net Profit-$35.20-$51.90-$39.57
Net Profit MarginN/AN/AN/A
Income ChangeN/A-47.44%23.76%

About Elicio Therapeutics, Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Elicio Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.85
$1.73
-5.21%
Sep 2026
$2.65
$1.82
-39.17%
Aug 2026
$2.84
$3.00
+6.95%
Jul 2026
$3.98
$2.81
-28.63%
Jun 2026
$11.53
$3.93
-65.16%
May 2026
$10.65
$11.28
+6.42%
Apr 2026
$10.78
$10.60
-1.21%
Mar 2026
$13.34
$10.73
-18.03%
Feb 2026
$7.91
$13.09
+69.23%
Jan 2026
$7.99
$7.74
-2.83%
Dec 2025
$9.27
$7.96
-14.64%
Nov 2025
$9.21
$9.32
+0.05%

ELTX Share Price FAQs